EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors

Jordyn Silverstein iD, Francis Wright, Michelle Wang iD, Arabella Young, Daniel Kim, Kimberly De Dios, Sam Brondfield, Zoe Quandt iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Jordyn Silverstein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Melanoma, Lung Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, UCSF, Resident Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As immune checkpoint inhibitors (CPI) are increasingly approved for cancer treatment, hospitalizations related to severe immune-related adverse events (irAE) will increase. Here, we identify patients hospitalized due to irAEs and describe survival outcomes across irAE, CPI, and cancer type.

Methods

We identified patients hospitalized at our institution from January 2012 to December 2020 due to irAEs. Survival was analyzed using Kaplan-Meier survival curves with log-rank tests.

Results

Of 3137 patients treated with CPIs, 114 (3.6%) were hospitalized for irAEs, resulting in 124 hospitalizations. Gastrointestinal (GI)/hepatic, endocrine, and pulmonary irAEs were the most common causes of irAE-related hospitalization. After CPI initiation, the average time to hospitalization was 141 days. Median survival from hospital admission was 980 days. Patients hospitalized due to GI/hepatic and endocrine irAEs had longer median survival than patients with pulmonary irAEs (795 and 949 days vs. 83 days [P < .001]). Patients with melanoma and renal cell carcinoma had longer median survival than patients with lung cancer (2792 days and not reached vs. 159 days [P < .001]). There was longer median survival in the combination group compared to the PD-(L)1 group (1471 vs. 529 days [P = .04]).

Conclusions

As CPI use increases, irAE-related hospitalizations will as well. These findings suggest that among patients hospitalized for irAEs, survival differs by irAE and cancer type, with worse survival for patients with irAE pneumonitis or lung cancer. This real-world data contributes to research pertaining to hospitalization due to severe irAEs, which may inform patient counseling and treatment decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellMelanomaLung NeoplasmsKidney NeoplasmsHumansHospitalizationRetrospective Studies

Stichwörter der Autor:innen

cancerhospitalizationimmune checkpoint inhibitorsimmunotherapyirAE

Autor:innen und Institutionen

  • Department of Internal Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, University of California, San Francisco, San Francisco, CA, USA.
  • Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
  • Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

ORCID-Profile: Jordyn Silverstein, Michelle Wang, Zoe Quandt

Förderung

  • NIDDK NIH HHS
  • UCSF
  • Resident Research
  • Medical School Research
  • American Diabetes Association

Zitieren

APA

Silverstein, J., Wright, F., Wang, M., Young, A., Kim, D., De Dios, K., Brondfield, S., & Quandt, Z. (2023). Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyad135

Vancouver

Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, et al. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. The Oncologist. 2023. doi:10.1093/oncolo/oyad135

BibTeX
@article{Silverstein2023,
  author = {Silverstein, Jordyn and Wright, Francis and Wang, Michelle and Young, Arabella and Kim, Daniel and De Dios, Kimberly and Brondfield, Sam and Quandt, Zoe},
  title = {Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad135}
}
Kostenlos starten →